- Home
- SWIN vs TPST Comparison
SWIN vs TPST Comparison
Compare SWIN & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- TPST
- Stock Information
- Founded
- SWIN 2017
- TPST 2011
- Country
- SWIN Hong Kong
- TPST United States
- Employees
- SWIN N/A
- TPST N/A
- Industry
- SWIN
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- TPST Health Care
- Exchange
- SWIN Nasdaq
- TPST Nasdaq
- Market Cap
- SWIN 32.1M
- TPST 33.0M
- IPO Year
- SWIN 2023
- TPST N/A
- Fundamental
- Price
- SWIN $3.06
- TPST $7.09
- Analyst Decision
- SWIN
- TPST Hold
- Analyst Count
- SWIN 0
- TPST 3
- Target Price
- SWIN N/A
- TPST $30.00
- AVG Volume (30 Days)
- SWIN 292.8K
- TPST 245.0K
- Earning Date
- SWIN 08-21-2025
- TPST 08-07-2025
- Dividend Yield
- SWIN N/A
- TPST N/A
- EPS Growth
- SWIN N/A
- TPST N/A
- EPS
- SWIN N/A
- TPST N/A
- Revenue
- SWIN $2,419,000.00
- TPST N/A
- Revenue This Year
- SWIN N/A
- TPST N/A
- Revenue Next Year
- SWIN $61.68
- TPST N/A
- P/E Ratio
- SWIN N/A
- TPST N/A
- Revenue Growth
- SWIN N/A
- TPST N/A
- 52 Week Low
- SWIN $1.16
- TPST $5.35
- 52 Week High
- SWIN $4.17
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- SWIN 79.41
- TPST 49.91
- Support Level
- SWIN $1.57
- TPST $6.87
- Resistance Level
- SWIN $3.48
- TPST $7.25
- Average True Range (ATR)
- SWIN 0.26
- TPST 0.67
- MACD
- SWIN 0.13
- TPST -0.02
- Stochastic Oscillator
- SWIN 78.05
- TPST 11.20
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.